“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
HOME > ACADEMIA
ACADEMIA
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
- JASDI Conducting Survey on Inconsistencies in Package Inserts of Similar Drugs; Will Come Up with Improvement Proposal by Year-End
August 19, 2013
- JSGM Initiates Plan to Unify Brand Names of Generic Fixed-dose Combination Drugs to Prevent Medication Errors
August 19, 2013
- St. Marianna University School of Medicine Hospital Ends Use of Diovan for Patients
August 16, 2013
- British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
- Japan Hypertension Society Sets Up Ethics Committee amid Diovan Fuss
August 8, 2013
- Japan Hypertension Society Deletes Citations of JIKEI Study from Treatment Guidelines
August 8, 2013
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
- Arzerra, Japan’s 1st Antibody for CLL, Will Expand Treatment Options: Dr Ogawa of Tokai Univ.
July 11, 2013
- Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
July 11, 2013
- Orencia Particularly Suitable for Elderly RA Patients: Prof. Takeuchi of Keio University
July 8, 2013
- “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
- NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
ページ
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…